| Year |
Citation |
Score |
| 2016 |
Renfro LA, Sargent DJ. Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group: the power of pooled individual patient data from multiple clinical trials. Chinese Clinical Oncology. 5: 80. PMID 28061544 DOI: 10.21037/cco.2016.12.02 |
0.327 |
|
| 2016 |
Althammer S, Steele K, Rebelatto M, Tan TH, Wiestler T, Schmidt G, Higgs B, Li X, Shi L, Jin X, Antal J, Gupta A, Ranade K, Binning G, Bellmunt J, ... ... Sargent DJ, et al. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts Journal For Immunotherapy of Cancer. 4. DOI: 10.1186/S40425-016-0191-4 |
0.506 |
|
| 2013 |
Renfro LA, Shi Q, Sargent DJ. Mining the ACCENT database: a review and update. Chinese Clinical Oncology. 2: 18. PMID 25841498 DOI: 10.3978/j.issn.2304-3865.2013.03.05 |
0.318 |
|
| 2013 |
Oba K, Paoletti X, Alberts S, Bang YJ, Benedetti J, Bleiberg H, Catalano P, Lordick F, Michiels S, Morita S, Ohashi Y, Pignon JP, Rougier P, Sasako M, Sakamoto J, ... Sargent D, et al. Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. Journal of the National Cancer Institute. 105: 1600-7. PMID 24108812 DOI: 10.1093/Jnci/Djt270 |
0.316 |
|
| 2013 |
André T, Iveson T, Labianca R, Meyerhardt JA, Souglakos I, Yoshino T, Paul J, Sobrero A, Taieb J, Shields AF, Ohtsu A, Grothey A, Sargent DJ. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Current Colorectal Cancer Reports. 9: 261-269. PMID 24032000 DOI: 10.1007/S11888-013-0181-6 |
0.301 |
|
| 2012 |
Sanoff HK, Carpenter WR, Martin CF, Sargent DJ, Meyerhardt JA, Stürmer T, Fine JP, Weeks J, Niland J, Kahn KL, Schymura MJ, Schrag D. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. Journal of the National Cancer Institute. 104: 211-27. PMID 22266473 DOI: 10.1093/Jnci/Djr524 |
0.32 |
|
| 2011 |
Yothers G, Sargent DJ, Wolmark N, Goldberg RM, O'Connell MJ, Benedetti JK, Saltz LB, Dignam JJ, Blackstock AW. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. Journal of the National Cancer Institute. 103: 1498-506. PMID 21997132 DOI: 10.1093/jnci/djr310 |
0.31 |
|
| 2010 |
Goldberg RM, Sargent DJ, McLeod H. Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics Transactions of the American Clinical and Climatological Association. 121. PMID 20697547 |
0.315 |
|
| 2006 |
Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts S. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 3347-53. PMID 16849748 DOI: 10.1200/Jco.2006.06.1317 |
0.301 |
|
| Show low-probability matches. |